摘要
将60例由扩张性心肌病、冠心病或瓣膜病变所致充血性心衰患者随机分为安慰剂及氨利酮组进行双盲对照观察,每组30例。结果安慰剂及氨利酮组心功能分别改善33.3%及46.7%,(p>0.05)。用药前、后用二维超声心动图仪测左心功能,安慰剂组无明显差异,氨利酮组除SI外,各项心功能均有明显改变(p<0.05),二组间比较除EF外,其余均有明显差异(p<0.05)。心脏X线片示心胸比值用药前、后安慰剂组平均值分别为0.59和0.58(p>0.05),氨利酮组从0.61缩小至0.57(p<0.05)。氨利酮组不良反应(34%)比安慰剂组多(10%)。
A randomized double blind trial on amrinone comparedwith placebo was carried out in 60 patients with congestive heart failurecaused by idiopathic cardiomyopathy, coronary heart disease, or valvularinsufficiency. The patients in group 1 (30 cases) received placebo 100 mgthree times daily for 5 days, while patients in group Ⅱ (30 cases) receivedamrinone 100 mg also three times daily. If there was no side effect, thedose was increased to 150 mg every time for 5 days, then 200 mg for 18days. The results showed that the percentage of improvement of cardiacfunction was 33. 3% and 46. 7% in group Ⅰ and Ⅱ, respectively, (p>0. 05) The two dimensional echocardiographic assessment of left ventricularfunction were evaluated before and after treatment. There were no signi-ficant differences in group 1. However, there were fisignicant differencesexcept for stroke index in group Ⅱ (p<0.05). There also were significantdifferences except for ejection fraction between two groups p<0. 05. The mean cardio-thorax ratio as determined by X-ray decreased from0.59 to 0.58 in group Ⅰ, (p>0.05) and from 0.61 to 0.57 in group Ⅱ,(p<0.05). The adverse reactions of group 11 (34%) were more common than thatof group 1 (10%), (p<0.05.) The side effects included arrhythmias, increased heart rate, gastro-intestinal discomfort and elevated SGPT. No evidence of thrombocytopeniawas observed. The results suggest that the improvement of cardiac perfor-mance is limited, with too many side effects. So, amrinone is not a de-sirable positive inotropic drug.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
1991年第3期177-181,共5页
The Chinese Journal of Clinical Pharmacology
